Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic

BRAF NRAS circulating tumour DNA melanoma mutation prognosis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Jul 2020
Historique:
received: 10 06 2020
revised: 03 07 2020
accepted: 06 07 2020
entrez: 16 7 2020
pubmed: 16 7 2020
medline: 16 7 2020
Statut: epublish

Résumé

Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of

Identifiants

pubmed: 32664549
pii: cancers12071871
doi: 10.3390/cancers12071871
pmc: PMC7409003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Roche
ID : No number

Références

Oncogene. 1989 Nov;4(11):1363-74
pubmed: 2682463
Melanoma Manag. 2019 Oct 18;6(3):MMT27
pubmed: 31807278
JAMA Oncol. 2016 Aug 1;2(8):1014-22
pubmed: 27055085
Ann Oncol. 2017 May 1;28(5):1130-1136
pubmed: 28327969
Mol Cell Biol. 1989 Jul;9(7):3114-6
pubmed: 2674680
J Transl Med. 2019 Sep 5;17(1):303
pubmed: 31488153
Expert Rev Clin Pharmacol. 2020 Mar 19;:1-15
pubmed: 31364890
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Ann Oncol. 2018 Feb 1;29(2):311-323
pubmed: 29216340
J Thorac Dis. 2019 Jan;11(Suppl 1):S113-S126
pubmed: 30775034
Oncotarget. 2018 Nov 16;9(90):36238-36249
pubmed: 30546839
J Invest Dermatol. 2014 May;134(5):1468-1470
pubmed: 24025553
BMC Cancer. 2018 Jul 9;18(1):726
pubmed: 29986670
Oncotarget. 2017 Feb 14;8(7):12501-12516
pubmed: 27980215
Curr Oncol Rep. 2019 Jul 29;21(9):76
pubmed: 31359162
Ann Oncol. 2018 Feb 1;29(2):490-496
pubmed: 29112704
Pharmacogenomics. 2019 Dec;20(18):1259-1270
pubmed: 31596166
Exp Dermatol. 2016 Oct;25(10):783-8
pubmed: 27194447
Ann Surg Oncol. 2020 Aug;27(8):2915-2926
pubmed: 31898103
J Clin Oncol. 2013 Sep 10;31(26):3205-11
pubmed: 23918947
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Tumori. 2020 Feb 6;:300891619900928
pubmed: 32026754
Expert Rev Anticancer Ther. 2020 Jan;20(1):53-62
pubmed: 31903803
Ann Oncol. 2019 May 1;30(5):815-822
pubmed: 30860590
Oncol Rep. 2014 Aug;32(2):808-14
pubmed: 24926836
Oncotarget. 2018 May 18;9(38):25265-25276
pubmed: 29861869
Clin Cancer Res. 2020 Apr 15;26(8):1924-1931
pubmed: 31852833
Ann Oncol. 2019 May 1;30(5):804-814
pubmed: 30838379

Auteurs

Guillaume Herbreteau (G)

Department of Biochemistry, CHU Nantes, 44093 Nantes, France.
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.

Audrey Vallée (A)

Department of Biochemistry, CHU Nantes, 44093 Nantes, France.
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.

Anne-Chantal Knol (AC)

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.

Sandrine Théoleyre (S)

Department of Biochemistry, CHU Nantes, 44093 Nantes, France.
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.

Gaelle Quéreux (G)

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.
Department of Dermato Cancerology, CHU Nantes, 44093 Nantes, France.
Centre d'investigation Clinique (CIC) 1413, CHU Nantes, 44093 Nantes, France.

Cécile Frénard (C)

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.
Department of Dermato Cancerology, CHU Nantes, 44093 Nantes, France.
Centre d'investigation Clinique (CIC) 1413, CHU Nantes, 44093 Nantes, France.

Emilie Varey (E)

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.
Centre d'investigation Clinique (CIC) 1413, CHU Nantes, 44093 Nantes, France.

Paul Hofman (P)

Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d'Azur, 06000 Nice, France.
Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) Inserm 1081/the National Center for Scientific Research (CNRS) 7284, Antoine Lacassagne Center, 06002 Nice, France.

Amir Khammari (A)

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.
Department of Dermato Cancerology, CHU Nantes, 44093 Nantes, France.
Centre d'investigation Clinique (CIC) 1413, CHU Nantes, 44093 Nantes, France.

Brigitte Dréno (B)

Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.
Department of Dermato Cancerology, CHU Nantes, 44093 Nantes, France.
Centre d'investigation Clinique (CIC) 1413, CHU Nantes, 44093 Nantes, France.

Marc G Denis (MG)

Department of Biochemistry, CHU Nantes, 44093 Nantes, France.
Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA) Inserm 1232, Centre Hospitalier Universitaire de Nantes (CHU Nantes), 44093 Nantes, France.

Classifications MeSH